Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Aardvark Therapeutics, Inc. (AARD)

1.3302 -0.0298 (-2.19%)
As of 10:27:10 AM EST. Market Open.
Trade AARD on Coinbase
Chart Range Bar
Loading chart for AARD
  • Previous Close 1.3600
  • Open 1.3700
  • Bid 1.3600 x 300
  • Ask 1.3800 x 100
  • Day's Range 1.3200 - 1.3960
  • 52 Week Range 0.9300 - 16.6000
  • Volume 45,967
  • Avg. Volume 591,996
  • Market Cap (intraday) 29.111M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -3.2100
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 7.50
  • Zacks Rating Neutral

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

aardvarktherapeutics.com

28

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AARD
89.87%
S&P 500 (^GSPC)
11.90%

1-Year Return

AARD
87.56%
S&P 500 (^GSPC)
11.98%

3-Year Return

AARD
91.24%
S&P 500 (^GSPC)
77.40%

5-Year Return

AARD
91.24%
S&P 500 (^GSPC)
65.41%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -14.39M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-20M
-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

1.50
7.50 Average
1.3302 Current
28.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/27/2026
Analyst Jones Trading
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 19 -> 10

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -40.38%

  • Return on Equity (ttm)

    -66.02%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -69.89M

  • Diluted EPS (ttm)

    -3.2100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    73.87M

  • Total Debt/Equity (mrq)

    0.90%

  • Levered Free Cash Flow (ttm)

    -46.9M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: